Navigating the New Drug Wave: Strategies for Value Creation and Patent Protection in China's Biotech Sector
Currently, the pace at which innovative drugs from international pharmaceutical companies enter the Chinese market is accelerating, and their numbers are increasing. Meanwhile, domestic new drug R&D enterprises are emerging in large numbers. Regulators welcome this vibrant and diverse landscape. Intense competition will inevitably lead to price reductions, and the National Healthcare Security Administration, as the ultimate payer, along with patients, will have more choices and reap the greatest benefits.
It is widely acknowledged within the industry that China lacks both the fertile ground for basic research, akin to the hundreds of billions of dollars invested by the U.S. National Institutes of Health (NIH), and a high-pricing commercial insurance payment system to provide high returns on high-risk research. Consequently, it is challenging for China to develop truly innovative first-in-class (FIC) drugs.
Homogenized “me-too” new drugs have entered an era of price wars. If innovative drugs are reduced to competing on price like generics, then what was the point of the initial persistence?
NO PATENT, NO DRUG: Patents are the armor and core competitiveness of biotech startups. Patent disputes have always been the main battlefield in new drug competition. How can companies ensure their "ironclad" patent protection remains intact while continuing to advance their pipelines?
In this environment, how should investors view the positioning and development of Chinese startup companies engaged in new drug research and development?
What R&D strategy should biotech startups adopt to grow and demonstrate their value?
How Should Patents Be Strategically Aligned as the Pipeline Advances?
We are honored to have invited experts in the field of new drugs to share their analysis and insights on overseas new drug development and patent layout.
Our original plan was to secure a salon venue with a capacity of no more than 50 attendees. As of August 27, registrations have exceeded 145, a level of interest that has far surpassed our expectations. To ensure that as many participants as possible can attend, we are currently evaluating alternative venues. Thank you once again for your enthusiasm and participation.
Registration for this forum is free, but spots are limited and available on a first-come, first-served basis!
Presentation Topic
For quite some time, scientists in the new drug development community and peers in the investment sector have closely followed and highly valued the articles and reports published by BiotechVC. This is because they consistently offer distinct perspectives and unique insights, which have, to varying degrees, prompted deeper reflection among certain drug developers and investors.
At this salon, the BiotechVC team will share their latest research findings, practical insights, and reflections.
Chen Feng, Partner at Youxuan Capital
Speaker Introduction:
Chen Feng, Founder of “Biotech Venture Capital,” Partner at Youxuan Capital, previously engaged in investment management at China International Capital Corporation (CICC) and Zhongzhi Enterprise Group. Columnist for the “Investor” website, member of the expert panel of China Pharmaceutical News (directly administered by the NMPA), and member of the Chinese New Drug Founders Club.
Biotech VC: Top-Rated Articles
"Stars and the Sea"
“Casual Talks on Due Diligence for Innovative Drugs” Series
“Calculating the Costs of New Drugs for the China Market Only”
“What Does Our Preferred ‘Me-Too’ Strategy Look Like?”
Dr. Shi Dongfang
Speaker Introduction:
Dr. Shi Dongfang, Founder, Chairman, and CEO of Jiangsu New Element Pharmaceutical. Prior to returning to China in 2012 to start his business, he spent 20 years in the United States and the United Kingdom engaged in the research and development of first-in-class innovative drugs for anti-tumor, anti-HCV, and type 2 diabetes treatments.
New Element Pharmaceutical targets the global market and independently develops Class 1.1 innovative drugs for gout, cancer, and non-alcoholic steatohepatitis (NASH). Its innovative anti-gout drug, ABP-671, has completed Phase 1a clinical trials in the United States, is scheduled to complete Phase 1b trials shortly, and will then advance to Phase 2. Clinical trial results indicate that a daily dose of 0.5 mg of ABP-671 may exhibit efficacy comparable to that of an 80 mg dose of benzbromarone, currently the leading gout medication on the market, while demonstrating a favorable safety profile. Its NASH therapeutic candidate, ABP-6016, and its first-in-class agent for gastric and colorectal cancers, ABP-431, are expected to enter Phase 1 clinical trials in the United States by the end of 2020.
The company has secured nearly RMB 80 million in financing and grants, is currently undertaking its Series B funding round, and plans to go public in 2021. It has developed detailed strategies for patent application and portfolio layout, clinical trials, and commercial operations both domestically and internationally.
Lv Pengtao
Speaker Introduction:
Lu Pengtao is the Managing Partner of Nanjing Situo Intellectual Property Agency. He graduated from the Department of Chemistry and Chemical Engineering at Southeast University. Since entering the intellectual property field in 2006, he has handled over 1,600 patent applications in the pharmaceutical and chemical sectors, as well as multiple patent litigation cases. He has participated in numerous projects involving patent information retrieval, value analysis, and patent commercialization, and has conducted dozens of IP-related training sessions for clients, demonstrating extensive practical experience in IP agency services and protection.
Currently primarily responsible for services including the prosecution and training of international and domestic patents, as well as intellectual property infringement and litigation.
Main Agenda
13:30-14:00 Registration
Confirmation of Attendee Arrival
14:00-15:00 Chen Feng, Founder of Biotech VC
“What Kind of Biotech Companies Do We Like?”
15:00-16:00 Shi Dongfang, Chairman and CEO of Jiangsu New Element Pharmaceutical
“Prioritizing Overseas Markets and Strategically Structuring Innovative Drug Pipelines”
16:00-16:30 Lv Pengtao, Founder of Situo Patent Company
“Reasonable Application and Global Layout of Patents for Innovative Drugs”
16:30-16:50 Interactive Exchange
Q&A Session
16:50-17:00 Group Photo
Commemorative Group Photo
17:00-17:30 Tea Break
Free Exchange
Friendly Reminder
Regarding Attendees:
1. Personnel from professional medical investment institutions, etc.;
2. Senior management and experienced R&D personnel at chemical and biopharmaceutical companies, etc.;
3. CRO Services for Pharmaceutical Companies, Project Initiation, Head of Business Development (BD)
Regarding Conference Registration:
Participation is free. Spaces are limited and available on a first-come, first-served basis.
Registration for this event is conducted online. Due to limited seating at the venue, prospective attendees are urged to register promptly!
The organizers will review the registration information of applicants, and confirmed attendees will receive relevant details. Attendees who fail to attend without a valid reason will be disqualified from participating in the Pharmaceutical Investment and M&A Club and other high-quality events organized by the hosts.
About the Organizer
Hosted by | Biotech VC
Co-organized by | Pharmaceutical Investment and M&A Club
Friendly Support | Tongxieyi, Drug Era, New Drug Founders Club, Pharmaceutical Times, Beike Society, VBBeat New Medicine
Date | September 10, 2019
Location | To be determined in Beijing (further notice will be given in early September)
Long-press to scan the QR code below
Pre-register Now
Conference Consultation:
Secretary-General of the Pharmaceutical Investment and M&A Club, Wei Yaxi
Chen Feng, Founder of Biotech VC